• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth - Product Image

HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth

  • Published: November 2012
  • Region: Global
  • 111 Pages
  • GBI Research

FEATURED COMPANIES

  • Abbott Laboratories
  • BMS
  • Gilead Sciences, Inc
  • GlaxoSmithKline (GSK)
  • Johnson & Johnson (J&J)
  • Merck
  • MORE

GBI Research, a leading business intelligence provider, has released its latest research, “HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth”. The report provides insights into the Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome) HIV/AIDS therapeutics market including market forecasts up to 2018. It provides an in-depth analysis of the major marketed products, as well as insights into the HIV/AIDS therapeutics R&D pipeline.

The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global HIV/AIDS therapeutics market. The report analyzes the market for HIV/AIDS therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. The report provides branded and generics segmentation in the therapeutic landscape segment. In addition, it analyzes the HIV/AIDS therapeutics market in India, China and Australia. The report discusses the global pipeline for all the HIV/AIDS molecules across various stages of development. The report is built using data and information sourced from READ MORE >

1.1 List of Tables
1.2 List of Figures

2 HIV/AIDS Therapeutics Market to 2018 - Introduction

3 HIV/AIDS Therapeutics Market to 2018 - Overview
3.1 Disease Overview
3.1.1 Diagnostic Tests for HIV
3.2 WHO Guidelines for HIV/AIDS Treatment
3.2.1 WHO Clinical Staging of HIV Disease in Adults and Adolescents
3.2.2 Summary of Changes to the WHO’s Guidelines on Initiation of ART based on CD4 Count and Clinical Staging
3.2.3 Summary of Changes to WHO’s Guidelines on First-line Antiretrovirals
3.2.4 Summary of Changes to the WHO’s Guidelines on Second-line Antiretrovirals
3.3 Drugs Classes Used in HIV/AIDS Treatment
3.3.1 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
3.3.2 Non-nucleoside Reverse Transcriptase Inhibitors
3.3.3 Protease Inhibitors
3.3.4 Fusion Inhibitors
3.3.5 CCR5 Co-receptor Antagonist
3.3.6 Integrase Inhibitors
3.3.7 Multi-class Combination Drugs
3.4 Key Marketed Products
3.4.1 Atripla
3.4.2 Truvada
3.4.3 Reyataz
3.4.4 Sustiva
3.4.5 Isentress
3.5 Advancements in HIV/AIDS Vaccine Research

4 HIV/AIDS Therapeutics Market to 2018 - Market Characterization and Forecast
4.1 Introduction
4.2 Revenue Forecast
4.2.1 Market Share by Drug Class (%), 2011
4.3 Branded Versus Generics Market Share (%), 2011
4.4 Market Share by Company (%), 2011
4.5 Annual Cost of Therapy
4.6 Treatment Usage Pattern
4.6.1 Diseased Population
4.6.2 Diagnosed Population
4.6.3 Prescription Population
4.7 HIV/AIDS Therapeutics Market - Drivers and Restraints
4.7.1 HIV/AIDS Therapeutics Market - Drivers
4.7.2 Market Restraints

5 HIV/AIDS Therapeutics Market to 2018 - The US
5.1 Market Overview
5.2 Revenue Forecast
5.3 Annual Cost of Therapy
5.4 Treatment Usage Pattern
5.4.1 Diseased Population
5.4.2 Diagnosed Population
5.4.3 Prescription Population

6 HIV/AIDS Therapeutics Market to 2018 - Top Five European Countries
6.1 Market Overview
6.2 Revenue Forecast: Top Five European Countries
6.3 Revenue by Geographical Segmentation
6.4 Annual Cost of Therapy
6.5 Treatment Usage Pattern
6.5.1 Diseased Population
6.5.2 Diagnosed Population
6.5.3 Prescription Population

7 HIV/AIDS Therapeutics Market to 2018 - Japan
7.1 Market Overview
7.2 Revenue Forecast
7.3 Annual Cost of Therapy
7.4 Treatment Usage Pattern
7.4.1 Diseased Population
7.4.2 Diagnosed Population
7.4.3 Prescription Population

8 HIV/AIDS Therapeutics Market to 2018 - Emerging Markets
8.1 China
8.1.1 Epidemiology
8.1.2 Important Events in China’s HIV/AIDS Policy Development
8.1.3 Clinical Trials in China
8.2 India
8.2.1 Overview
8.2.2 National AIDS Control Programs
8.2.3 Treatment Guidelines
8.2.4 Trade Related Aspects of Intellectual Property Rights Agreement and its Impact on Generics
8.2.5 Recent Developments in HIV/AIDS Therapeutics Market in India
8.3 Australia
8.3.1 Overview
8.3.2 Highly Specialized Drugs (Section 100) Program

9 HIV/AIDS Therapeutics Market to 2018 - Pipeline Analysis
9.1 Overview
9.2 Promising Molecules in Late Stages of Clinical Development
9.2.1 Stribild (Quad)
9.2.2 Cobicistat
9.2.3 JTK-303
9.2.4 1349572
9.2.5 572-Trii

10 HIV/AIDS Therapeutics Market to 2018 - Competitive Landscape
10.1 Introduction
10.2 Major Company Profiles
10.2.1 Gilead Sciences, Inc
10.2.2 GlaxoSmithKline (GSK)
10.2.3 BMS
10.2.4 Abbott Laboratories
10.2.5 Merck
10.2.6 Johnson & Johnson (J&J)
10.2.7 Roche

11 HIV/AIDS Therapeutics Market to 2018 - Strategic Consolidations
11.1 Deals by Year
11.2 Deals by Type
11.2.1 Deals by Value
11.3 Deals by Geography
11.4 Summary of Major M&A Deals
11.4.1 Daiichi Sankyo Acquires Majority Stake in Ranbaxy Labs
11.4.2 Endo Pharma Acquires Indevus Pharma
11.5 Summary of Major Licensing Deals
11.5.1 GlaxoSmithKline Enters into Licensing Agreement with Idenix Pharma
11.5.2 BMS Enters into Licensing Agreement with Oncolys BioPharma
11.6 Summary of Major Partnerships
11.6.1 GlaxoSmithKline Enters into an Agreement with Concert Pharma
11.6.2 Chemrar Enters into Joint Venture Agreement with Rusnano
11.6.3 GenVec Enters into an Agreement with SAIC-Frederick

12 HIV/AIDS Therapeutics Market to 2018 - Appendix
12.1 Market Definitions
12.2 Abbreviations
12.3 Bibliography
12.4 Research Methodology
12.4.1 Coverage
12.4.2 Secondary Research
12.4.3 Primary Research
12.5 Therapeutic Landscape
12.5.1 Epidemiology-based Forecasting
12.5.2 Market Size by Geography
12.6 Geographical Landscape
12.7 Pipeline Analysis
12.8 Competitive Landscape
12.8.1 Expert Panel Validation
12.9 Contact Us
12.10 Disclaimer

1.1 List of Tables

Table 1: HIV/AIDS Therapeutics Market to 2018, WHO Clinical Staging of HIV Disease in Adults and Adolescents, 2010
Table 2: HIV/AIDS Therapeutics Market to 2018, Summary of Changes to the WHO’s Guidelines on Initiation of Antiretroviral Therapy Based on CD4 Count and Clinical Staging, 2010
Table 3: HIV/AIDS Therapeutics Market to 2018, Summary of Changes to WHO’s Guidelines on First-line Antiretrovirals, 2010
Table 4: HIV/AIDS Therapeutics Market to 2018, Summary of Changes to WHO’s Guidelines on Second-line Antiretrovirals, 2010
Table 5: HIV/AIDS Therapeutics Market to 2018, Nucleoside/Nucleotide Reverse Transcriptase Inhibitors, Global Sales ($m), 2011
Table 6: HIV/AIDS Therapeutics Market to 2018, Non-Nucleoside Reverse Transcriptase Inhibitors, Global Sales ($m), 2011
Table 7: HIV/AIDS Therapeutics Market to 2018, Protease Inhibitors, Global Sales ($m), 2011
Table 8: HIV/AIDS Therapeutics Market to 2018, Fusion Inhibitors, Global Sales ($m), 2011
Table 9: HIV/AIDS Therapeutics Market to 2018, CCR5 Co-receptor Antagonist Global Sales ($m), 2011
Table 10: HIV/AIDS Therapeutics Market to 2018, Integrase Inhibitors Global Sales ($m), 2011
Table 11: HIV/AIDS Therapeutics Market to 2018, Multi-class Combination Drugs, Global Sales ($m), 2011
Table 12: HIV/AIDS Therapeutics Market to 2018, Global, Market Share of Key Products (%), 2011
Table 13: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Revenue ($bn), 2004-2011
Table 14: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Revenue Forecast ($bn), 2011-2018
Table 15: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Annual Cost of Therapy ($), 2004-2011
Table 16: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Annual Cost of Therapy Forecast ($), 2011-2018
Table 17: HIV/AIDS Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2004-2011
Table 18: HIV/AIDS Therapeutics Market, Top Seven Markets, Treatment Usage Pattern Forecast (‘000), 2011-2018
Table 19: HIV/AIDS Therapeutics Market to 2018, The US, Patent Expiries, 2012-2018
Table 20: HIV/AIDS Therapeutics Market to 2018, The US, Revenue ($bn), 2004-2011
Table 21: HIV/AIDS Therapeutics Market to 2018, The US, Revenue Forecast ($bn), 2011-2018
Table 22: HIV/AIDS Therapeutics Market to 2018, The US, Annual Cost of Therapy ($), 2004-2011
Table 23: HIV/AIDS Therapeutics Market to 2018, The US, Annual Cost of Therapy Forecast ($), 2011-2018
Table 24: HIV/AIDS Therapeutics Market to 2018, The US, Treatment Usage Pattern (‘000), 2004-2011
Table 25: HIV/AIDS Therapeutics Market to 2018, The US, Treatment Usage Pattern Forecast (‘000), 2011-2018
Table 26: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Revenue ($bn), 2004-2011
Table 27: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Revenue Forecast ($bn), 2011-2018
Table 28: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Revenue by Geographical Segmentation ($m), 2004-2011
Table 29: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Revenue Forecast by Geographical Segmentation ($m), 2011-2018
Table 30: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy ($), 2004-2011
Table 31: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy Forecast ($), 2011-2018
Table 32: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Treatment Usage Pattern (‘000), 2004-2011
Table 33: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Treatment Usage Pattern Forecast (‘000), 2011-2018
Table 34: HIV/AIDS Therapeutics Market to 2018, Japan, Revenue ($m), 2004-2011
Table 35: HIV/AIDS Therapeutics Market to 2018, Japan, Revenue Forecast ($m), 2011-2018
Table 36: HIV/AIDS Therapeutics Market to 2018, Japan, Annual Cost of Therapy ($), 2004-2011
Table 37: HIV/AIDS Therapeutics Market to 2018, Japan, Annual Cost of Therapy Forecast ($), 2011-2018
Table 38: HIV/AIDS Therapeutics Market to 2018, Japan, Treatment Usage Pattern (‘000), 2004-2011
Table 39: HIV/AIDS Therapeutics Market to 2018, Japan, Treatment Usage Pattern Forecast (‘000), 2011-2018
Table 40:HIV/AIDS Therapeutics Market, China, Diseased Population (‘000), 2005-2011
Table 41: HIV/AIDS Therapeutics Market, Pipeline Molecules, China, 2012
Table 42: HIV/AIDS Therapeutics Market to 2018, India, ART Centre Coverage and Patients on First-line Therapy, 2005-2010
Table 43: HIV/AIDS Therapeutics Market to 2018, India, HIV/AIDS Prevalence, 2004-2009
Table 44: HIV/AIDS Therapeutics Market to 2018, India, Treatment Guidelines, 2011
Table 45: HIV/AIDS Therapeutics Market to 2018, Australia, Number of HIV Cases and MSM (%), 2001-2010
Table 46: HIV/AIDS Therapeutics Market to 2018, Australia, List of Approved Medications Under Highly Specialized Drugs (Section 100) Program, 2012
Table 47: HIV/AIDS Therapeutics Market to 2018, Australia, Number of People Prescribed ART through the Highly Specialized Drugs (S100) Program, 2006-2010
Table 48: HIV Therapeutics Market, Global, Number of Molecules in Pipeline by Phase, 2012
Table 49: HIV Therapeutics Market, Global, Promising Molecules in Late Stages of Clinical Development, 2012
Table 50: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Type, 2008-2012
Table 51: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Mergers and Acquisitions Deals, 2008-2012
Table 52: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Partnership Deals, 2008-2012
Table 53: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Partnership Deals, 2008-2012
Table 54: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Licensing Deals, 2008-2012
Table 55: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Licensing Deals, 2008-2012
Table 56: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Licensing Deals, 2008-2012
Table 57: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Value ($m), 2008-2012
Table 58: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Geography, 2008-2012

1.2 List of Figures
Figure 1: HIV/AIDS Therapeutics Market to 2018, Global, Treatment Algorithm, 2012
Figure 2: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Revenue Forecast ($bn), 2004-2018
Figure 3: HIV/AIDS Therapeutics Market to 2018, Global, Market Share by Drug Class (%), 2011
Figure 4: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Branded Versus Generics Market Share (%), 2011
Figure 5: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Market Share by Company (%), 2011
Figure 6: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Annual Cost of Therapy ($), 2004-2018
Figure 7: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Treatment Usage Pattern (‘000), 2004-2018
Figure 8: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Drivers and Restraints, 2012
Figure 9: HIV/AIDS Therapeutics Market to 2018, The US, Revenue Forecast ($bn), 2004-2018
Figure 10: HIV/AIDS Therapeutics Market to 2018, The US, Annual Cost of Therapy ($), 2004-2018
Figure 11: HIV/AIDS Therapeutics Market to 2018, The US, Treatment Usage Pattern (‘000), 2004-2018
Figure 12: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Revenue Forecast ($bn), 2004-2018
Figure 13: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Revenue Forecast by Geographical Segmentation ($m), 2004-2018
Figure 14: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy Forecast ($), 2004-2018
Figure 15: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Treatment Usage Pattern (‘000), 2004-2018
Figure 16: HIV/AIDS Therapeutics Market to 2018, Japan, Revenue Forecast ($m), 2004-2018
Figure 17: HIV/AIDS Therapeutics Market to 2018, Japan, Annual Cost of Therapy ($), 2004-2018
Figure 18: HIV/AIDS Therapeutics Market to 2018, Japan, Treatment Usage Pattern (‘000), 2004-2018
Figure 19: HIV/AIDS Therapeutics Market, China, Diseased Population (‘000), 2005-2011
Figure 20: HIV/AIDS Therapeutics Market, Important Events in China’s HIV/AIDS Policy Development, 1985-2012
Figure 21: HIV/AIDS Therapeutics Market to 2018, India, ART Centre Coverage and Patients on First Line Therapy, 2005-2010
Figure 22: HIV/AIDS Therapeutics Market to 2018, India, HIV/AIDS Prevalence, 2004-2009
Figure 23: HIV/AIDS Therapeutics Market to 2018, Australia, Number of Diagnosed HIV Cases and MSM (%), 2001-2010
Figure 24: HIV/AIDS Therapeutics Market to 2018, Global, Pipeline by Phase (%), 2012
Figure 25: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Market Share by Company (%), 2011
Figure 26: HIV/AIDS Therapeutics Market to 2018, Gilead Sciences, SWOT Analysis, 2012
Figure 27: HIV/AIDS Therapeutics Market to 2018, GSK, SWOT Analysis, 2012
Figure 28: HIV/AIDS Therapeutics Market to 2018, BMS, SWOT Analysis, 2012
Figure 29: HIV/AIDS Therapeutics Market to 2018, Abbott, SWOT Analysis, 2012
Figure 30: HIV/AIDS Therapeutics Market to 2018, Merck, SWOT Analysis, 2012
Figure 31: HIV/AIDS Therapeutics Market to 2018, J&J, SWOT Analysis, 2012
Figure 32: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Year, 2008-2012
Figure 33: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Type (%), 2008-2012
Figure 34: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Value (%), 2008-2012
Figure 35: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Geography (%), 2008-2012
Figure 36: GBI Research Market Forecasting Model

Stribild Introduction to Reinforce HIV/AIDS Revenues as Key Patents Expire

Gilead Science’s combination drug Stribild (previously known as the “Quad pill”) is expected to bolster the HIV/AIDS therapeutics market as a number of significant medications go off-patent over the next few years, states business intelligence provider GBI Research in its latest publication.

Forecasts from the firm’s latest report indicate that the global HIV/AIDS therapeutics market will increase in value at a Compound Annual Growth Rate (CAGR) of 7% between the years 2011 and 2018, from $13.5 billion to $21.8 billion.

As a consequence of the on-going patent-cliff, this predicted growth rate is less than the market experienced in previous years. Between 2004 and 2011, the market experienced a more impressive CAGR of 12.5%, but due to the impending expiry of key medications, including Sustiva and Reyataz (both produced by Bristol-Myers Squibb) in 2014 and 2017 respectively, a more modest increase is predicted.

However, the market is not without promise. The multi-class fixed dose combination tablet from Gilead Sciences, Atripla, saw global revenue increase from $2.9 billion in 2010 to $3.2 billion last year, while potential blockbuster Stribild was approved by the US Food and Drug Administration in August of this year and is expected to make a major impact.

Gilead announced Stribild's initial price as $28,500, which is one-third greater than that of Atripla, but with impressive efficacy and strong patient compliance, GBI Research do not expect this higher cost to be a significant barrier to widespread use.

Last year’s sales figures show Gilead as being the greatest revenue shareholder of the world’s top seven markets, with 36%. With less than half of that number, Bristol-Myers Squibb came second with 16%, while ViiV Healthcare completed the top three with a 13% segment.

* HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth

This report provides insights into the Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome) HIV/AIDS therapeutics market including market forecasts up to 2018.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

- Gilead Sciences, Inc
- GlaxoSmithKline (GSK)
- BMS
- Abbott Laboratories
- Merck
- Johnson & Johnson (J&J)
- Roche

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos